<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018209</url>
  </required_header>
  <id_info>
    <org_study_id>PANAM (29BRC19.0001)</org_study_id>
    <nct_id>NCT04018209</nct_id>
  </id_info>
  <brief_title>Aquagenic Pruritus in Myeloproliferative Neoplasms</brief_title>
  <acronym>PANAM</acronym>
  <official_title>Aquagenic Pruritus in Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Description of the characteristics of aquagenic pruritus expressed by patients suffering from
      myeloproliferative neoplasms.

      Prospective work based on the distribution of a dedicated questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with myeloproliferative neoplasms identified and followed in French Hospitals.
      Patients could be followed for polycythemia vera or essential thrombocythemia or primary
      myelofibrosis.

      Distribution of the questionnaire to each patient with myeloproliferative neoplasm (treated
      or not) suffering from aquagenic pruritus.

      Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at
      the end.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2019</start_date>
  <completion_date type="Anticipated">January 9, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 9, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description of pruritus in patients with myeloproliferative neoplasms</measure>
    <time_frame>at the time of questionnaire completion (Day 0)</time_frame>
    <description>Intensity of pruritus (visual analogic scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of therapies used to treat pruritus</measure>
    <time_frame>at the time of questionnaire completion (Day 0)</time_frame>
    <description>Name of drugs used</description>
  </secondary_outcome>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with one of three Philadelphia positive non-chromosome myeloproliferative
        neoplasms: polycythemia vera (PV), essential thrombocythemia (TE) or primary myelofibrosis
        (PMF).

        And suffering (or having suffered) from aquagenic pruritus.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with one of three non-chromosomal Philadelphia-positive myeloproliferative
             neoplasms: polycythemia vera (PV), essential thrombocythemia (ET), and primary
             myelofibrosis (PMF).

          -  Suffering (or having suffered) from aquagenic pruritus.

          -  No age limit, but major

          -  Patient having formulated his non-opposition

        Exclusion Criteria:

          -  Patients with MPN with non-aquagenic pruritus,

          -  Patients with another hematologic disease and aquagenic pruritus

          -  Patients unable to complete the questionnaire.

          -  Patients with physical or mental disabilities to formulate non-opposition

          -  Refusal of participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Christophe IANOTTO</last_name>
    <phone>+33298222523</phone>
    <email>jean-Christophe.ianotto@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurent MISERY</last_name>
    <phone>+33298223315</phone>
    <email>laurent.misery@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>05</name>
      <address>
        <city>Lyon</city>
        <state>Auvergne Rhônes-alpes</state>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck-Emmanuel NICOLINI</last_name>
      <phone>+33469856193</phone>
      <email>franc-emmanuel.nicolini@lyon-unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>10</name>
      <address>
        <city>Quimper</city>
        <state>Brestagne</state>
        <zip>29000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal HUTIN</last_name>
      <phone>+33296017123</phone>
      <email>p.hutin@ch-cornouaille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>11</name>
      <address>
        <city>Morlaix</city>
        <state>Bretagne</state>
        <zip>29600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed MALOU</last_name>
      <phone>+33298791297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>09</name>
      <address>
        <city>Saint-Brieuc</city>
        <state>Bretagne</state>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anaïg DAGORNE</last_name>
      <phone>+33296017123</phone>
      <email>anaig.dagorne@ch-stbrieuc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>07</name>
      <address>
        <city>Saint-Louis</city>
        <state>Grand Est</state>
        <zip>68300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel RAFFOUX</last_name>
      <phone>+33142499649</phone>
      <email>emmanuel.raffoux@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>03</name>
      <address>
        <city>Annecy</city>
        <state>Haute-Savoie</state>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale CONY-MAKHOUL</last_name>
      <phone>+33450636431</phone>
      <email>pconymakhoul@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>04</name>
      <address>
        <city>Roubaix</city>
        <state>Hauts-de-France</state>
        <zip>59100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathieu WEMEAU</last_name>
      <phone>+33320993270</phone>
      <email>mathieu.wemeau@chu-roubaix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>08</name>
      <address>
        <city>Rochefort</city>
        <state>Nouvelle Aquitaine</state>
        <zip>17300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume DENIS</last_name>
      <phone>+33546885050</phone>
      <email>guillaume.denis@ch-rochefort.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>06</name>
      <address>
        <city>Angers</city>
        <state>Pays De La Loire</state>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corentin ORVAIN</last_name>
      <phone>+33615270461</phone>
      <email>corentin.orvain@univ.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>02</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence LE GROS</last_name>
      <phone>+33145593620</phone>
      <email>Laurence.legros@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>01</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe Ianotto</last_name>
      <email>jean-christophe.ianotto@chu-brest.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pruritus</keyword>
  <keyword>Myeloproliferative Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning six months and ending five years following the publication</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be rewiewed by internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

